CAS No. |
39219-28-8 |
英文名称 |
(8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene |
别名 |
17β-Methoxy-3-propoxyestra-1,3,5(10)-triene;17()-17-Methoxy-3-propoxy-estra-1,3,5(10)-triene;3-Propoxy-17-methoxyestra-1,3,5(10)-triene;3-Propoxy-17-methoxyoestra-1,3,5(10)-triene;3-Propoxy-17b-methoxyestra-1,3,5(10)-trien;17(b)-17-Methoxy-3-propoxy-estra-1,3,5(10)-triene;PROMESTRIENE;17-BETA-ESTRADIOL 3-PROPYL ETHER 17-METHYL ETHER |
标准英文名 |
(8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene |
分子式 |
C22H32O2 |
分子量 |
328.50
|
精确分子量 |
328.24
|
SMILES |
CCCOC1=CC=C2C(=C1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](OC)CC[C@@H]12 |
标准SMILES |
CO[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=CC=C4[C@H]3CC[C@@]21C)OCCC |
用途 |
Promestriene is a topical estrogenic agent used for the prevention and treatment of atrophic vaginitis and other estrogen deficiency-related conditions in the vulvovaginal area. It is indicated for:
1. Topical cream or ointment: Treatment of atrophic lesions of the vulva, vestibule, and vaginal introitus.
2. Vaginal capsules: Management of vaginal atrophy due to estrogen deficiency; promotion of healing in mucosal injuries of the cervix, vagina, and vulva caused by childbirth, local surgery, or physical therapies (e.g., laser, cryotherapy, or cauterization).
It exerts strictly local estrogenic effects by thickening the vaginal epithelium, restoring vaginal pH balance, improving the vaginal microenvironment, and enhancing local resistance to infection, without systemic estrogenic activity. Due to its minimal systemic absorption, it avoids the systemic risks associated with long-term local estrogen therapy and is particularly suitable for patients with estrogen-dependent diseases.
Promestriene is also used in combination therapies:
- Combined with recombinant human interferon α-2b vaginal effervescent capsules for atrophic vaginitis (total effective rate: 96%).
- Combined with live Lactobacillus preparations for atrophic vaginitis (cure rate: 95%).
- Combined with metronidazole for bacterial vaginosis (total effective rate: 92.50%, low recurrence, no adverse reactions reported). |
InChIKey |
IUWKNLFTJBHTSD-AANPDWTMSA-N |